Investing.com - Aptevo Therapeutics (NASDAQ: APVO) reported first quarter EPS of $-1.53, in line with the analyst estimate of $-1.53. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.
Aptevo Therapeutics's stock price closed at $2.04. It is up 0% in the last 3 months and down -67.62% in the last 12 months.
Aptevo Therapeutics saw 0 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Aptevo Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Aptevo Therapeutics's Financial Health score is "good performance".
Check out Aptevo Therapeutics's recent earnings performance, and Aptevo Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar